NeuroRx, Inc.
913 North Market Street
Suite 200
Wilmington
Delaware
19801
United States
Tel: 973-442-1555 ext. 116
Website: http://www.neurorxpharma.com/
69 articles with NeuroRx, Inc.
-
Relief Reports that its U.S. Collaboration Partner has Announced that the U.S. National Institutes of Health Study of Aviptadil in Critical COVID-19 is Cleared to Complete Full Enrollment
2/16/2022
RELIEF THERAPEUTICS Holding SA reported that the parent company, NRx Pharmaceuticals, Inc., of its collaboration partner with respect to aviptadil, NeuroRx, Inc., has announced results of a review conducted by the Therapeutics and Prevention Data Safety and Monitoring Board of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health on February 14, 2022.
-
Relief Reports US Collab. Partner Announces Submission to FDA seeking EUA for Aviptadil for Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
1/6/2022
RELIEF THERAPEUTICS reported that the parent company, NRx Pharmaceuticals, Inc., of its collaboration partner with respect to aviptadil, NeuroRx, Inc. has announced that it has submitted an application to the FDA seeking EUA for the use of aviptadil to treat patients with critical COVID-19 who are at immediate risk of death from respiratory failure despite treatment with approved therapy including Remdesivir and who are ineligible for enrollment into the ACTIV-3b NIH-sponsored trial.
-
NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP, Following Merger Between NeuroRx, Inc. and Big Rock Partners Acquisition Corp (Nasdaq:BRPA)
5/25/2021
Newly formed publicly traded company NRx Pharmaceuticals, Inc. (NRx) to be traded under the ticker symbol "NRXP" on the Nasdaq Global Market
-
NeuroRx Announces Zyesami™ (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir
4/6/2021
NeuroRx, Inc. reports that Aviptadil, to be supplied by NeuroRx, has been identified by the National Institutes of Health as one of two drugs selected for inclusion in a phase III multicenter clinical trial that will include the United States and multiple foreign countries.
-
Clinical Catch-Up: March 29-April 2
4/5/2021
It was a busy week for clinical trial news. Here’s a look. -
NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19
3/29/2021
NeuroRx, Inc. reports 60-day results of the Phase 2b/3 trial of intravenously-administered ZYESAMI™ for the treatment of respiratory failure in critically-ill patients with COVID-19, which is being developed in collaboration with Relief Therapeutics Holding AG.
-
NeuroRx Announces Completion of Data Analysis in Phase 2b/3 Clinical Trial of ZYESAMI™ for the Treatment of COVID-19 Respiratory Failure
3/26/2021
NeuroRx, Inc. announces completion of top line data analysis of the 60-day results in its phase 2b /3 clinical trial, conducted under FDA Fast Track Designation, of ZYESAMI™
-
UPDATE: NeuroRx Announces Dosing of First Patient with ZYESAMI™ in P2/3 Clinical Study for the Treatment of Moderate and Severe COVID-19 (AVICOVID-2)
3/19/2021
NeuroRx, Inc. announced the first patient in its P2/3 study of inhaled ZYESAMI™ in the treatment of moderate and severe COVID-19 was dosed at the University of California Irvine.
-
NeuroRx Announces Dosing of First Patient with ZYESAMI™ in P2/3 Clinical Study for the Treatment of Moderate and Severe COVID-19 (AVICOVID-2)
3/19/2021
NeuroRx, Inc. announced the first patient in its P2/3 study of inhaled ZYESAMI™ in the treatment of moderate and severe COVID-19 (AVICOVID-2) was dosed at the University of California Irvine
-
NeuroRx Announced that RLF-100(TM) has Demonstrated Ten-Day Accelerated Recovery from Respiratory Failure among Patients with Severe Covid-19 Treated with HFNO at 28 Day Interim Endpoint
2/24/2021
RELIEF THERAPEUTICS Holding AG, a biopharmaceutical company with its lead compound RLF-100 in advanced clinical development, announces that NeuroRx, Inc. has reported data from the Phase 2b/3 trial of RLF-100 for the treatment of Respiratory Failure in Critical COVID-19 patients.
-
NeuroRx Announces that ZYESAMI™ (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure in Critically Ill Patients with Covid-19 Treated with High Flow Nasal Oxygen at 28-Day Interim Endpoint
2/23/2021
NeuroRx to File for Emergency Use Authorization in This Patient Population if Positive Results Continue to be Demonstrated at Day-60 Endpoint in Line with FDA's New Guidance
-
NeuroRx reports Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ (aviptadil) in Reducing Hospital Stay among Patients with Respiratory Failure due to Critical COVID-19
2/9/2021
NeuroRx, Inc. today reported preliminary results from their Phase 2b/3 trial of ZYESAMI™ (aviptadil, previously RLF-100) performed in collaboration with Relief Therapeutics Holdings, AG (SIX:RLF;OTCQB:RLFTF) in patients with respiratory failure due to Critical COVID-19.
-
NeuroRX/Relief Therapeutics' COVID-19 Respiratory Distress Drug Significantly Reduces Hospital Stay
2/9/2021
ZYESAMI is intended to block the replication of SARS-CoV-2 in the ATII cell, as well as cytokine synthesis, thereby relieving respiratory distress. It is the only treatment in development that targets these ATII cells, and if approved, would be the first drug on the market for COVID-19 patients c... -
NeuroRx Initiates Phase 2/3 Study of Inhaled ZYESAMI™ for Severe COVID-19 with UCI Health
2/3/2021
NeuroRx, Inc. today announced initiation of a Phase 2/3 clinical trial investigating the role of inhaled ZYESAMI™ (aviptadil) for the treatment of patients with Severe COVID-19 in partnership with UCI Health of the University of California, Irvine.
-
Clinical Catch-Up: January 11-15
1/18/2021
The year is starting to pick up in terms of clinical trial announcements. Here’s a look at last week’s news. -
Like many biopharma companies, the global COVID-19 pandemic has caused delays while also offering opportunities for NeuroRx.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 12, 2021.
-
NeuroRx, Relief, and Quantum Leap announce the inclusion of ZYESAMI™ (RLF-100™: aviptadil) in the I-SPY COVID-19 Trial
1/11/2021
NeuroRx, Inc. and RELIEF THERAPEUTICS Holding AG, and the Quantum Leap Healthcare Collaborative of San Francisco announce that NeuroRx and QLHC have signed a Clinical Trial Participation Agreement for the inclusion of ZYESAMI™ in the I-SPY COVID-19 Clinical Trial.
-
It’s not particularly surprising that there wasn’t a lot of clinical trial news between Christmas and New Year’s, although there was some. Here’s a look.
-
NeuroRx and Relief Conclude Enrollment in their Phase 2b/3 Trial of RLF-100™ for Critical COVID-19 with Respiratory Failure
12/30/2020
NeuroRx, Inc. and RELIEF THERAPEUTICS Holding AG announced the conclusion of enrollment in the phase 2b/3 trial of ZYESAMI™ for the treatment of Respiratory Failure in patients with Critical COVID-19.